SOURCES SOUGHT
65 -- Reagents
- Notice Date
- 3/29/2017
- Notice Type
- Sources Sought
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 3155, MSC 9593, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NIDA-SSSA-SS-2017-285
- Archive Date
- 4/20/2017
- Point of Contact
- Stacey M Polk, Phone: 301-480-2445
- E-Mail Address
-
spolk@nida.nih.gov
(spolk@nida.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background: The National Institutes of Health (NIH) is the nation's leading medical research agency. Its mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people's health and save lives. NCGC, Matrix, ADST and Tox21 biology groups routinely screen their large collection of small molecules (450,000 compounds in dose response, equating to >2 million wells) against potential therapeutic targets of interest. RNAi biology also routinely screens their several hundred plate library collection of siRNA against potential therapeutic targets of interest. We anticipate using these reagent kits to screen a multitude of assays over the next year. NCGC associated projects include NNMT1, NMNT1, Merkel Cell Carcinoma Project, Matrix projects, and PCDR project. Purpose and Objectives: The purpose of this procurement is to procure four each bottles of Caspase-Glo® 3/7 Assay, Nano-Glo(R) Luciferase Assay, kits consisting of custom MTase-Glo(TM) Methyltransferase Assay, bottles of CellTiter-Glo 3D cell viability assay, Real-time Glo Annexin V Apoptosis Assay, ten each CS1838A01, and bottles of CellTiter-Glo One Solution Assay. These reagent kits are necessary in order to screen a multitude of assays over the next year. Purchase Description The Government requires the following: a.Four (4) size 100 mL bottles of Caspase-Glo® 3/7 Assay Catalog # G8092 Government's Essential features: •Homogenous luminescent assay to measure caspase 3/7 activities •Provide a proluminescent caspase-3/7 DEVD-aminoluciferin substrate •The thermostable luciferase in reagent must be optimized for caspase-3/7 activity, luciferase activity, and cell lysis •Must be able to use with with multiwell plate formats and either purified enzyme or cells in culture •Extended-glow signal should last minimum 3 hours to allow us time to read all plates •Maximum sensitivity must be achieved by no longer than 1 hour b.One (1) Kit consisting of 10 size 100ml bottles of Nano-Glo(R) Luciferase Assay Catalog # N1150 Government's Essential features: •Low background formiulation for increased sensitivity •Half-life of 120 hours c.Five (5) kits consisting of MTase-Glo(TM) Methyltransferase Assay, Custom V7603X - 1 kit (10 x 2,000 assays) •A120C - 10 ea •A233B - 10 ea •V760X - 10 ea •V761X - 10 ea Government's essential features •Should monitor formation of reaction product S-adenosul homocysteine •Detects changes in broad range of methylases •Must be optimized for high throughput screening applications •No fluorescence interference d.Four (4) each 100ml bottles of CellTiter-Glo 3D cell viability assay Item # G9683 Government's essential features •Data can be recorded in 30 minutes or less with half-life of >3 hours •Robust lytic capacity •For use with microtissues in 3D cell culture e.Ten (10) Real-time Glo Annexin V Apoptosis Assay Item # CS1838A01 •Annexin V-LgBiT Reagent •Annexin V-SmBiT Reagent •Annexin V NanoBiT Substrate •CaCl2 Solution •Necrosis Detection Reagent Government's essential features •Bright signal, reduced background improves sensitivity •Usable from benchtop to 1536 well plates f.Two (2) 500 ml bottles of CellTiter-Glo One Solution Assay Item # G8462 Government's essential need: •Stable luminescence beginning at 10 mins to >3 hours •Can measure cells below traditional detection limits •Frozen, ready to use format •Indicate presence of metabolically active cells Anticipated Period of Performance/Delivery Date: Within 30 days ARO Capability statement /information sought. Contractors that believe they possess the ability to provide the requirement should submit documentation of their ability to meet each of the project requirements to the Contract Specialist. The response should directly and specifically state in the, capabilities statement, which project requirements you can supply. Contractors must also provide their Company Name, DUNS Number, Physical Address, Point of Contact, and Size and Type of Business (e.g., 8(a), HubZone, etc.) pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. The information submitted must be must be in an outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. The response must include the respondents' technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses (capability statements) sent in response to this Sources Sought Notice must be submitted electronically (via e-mail) to the Contract Specialist. Facsimile responses are NOT accepted. The response must be submitted to Stacey Polk, Contract Specialist at spolk@nida.nih.gov. The response must be received no later than the close date of this notice. "Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/HHS-NIH-NIDA-SSSA-SS-2017-285/listing.html)
- Place of Performance
- Address: National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland, 20850, United States
- Zip Code: 20850
- Zip Code: 20850
- Record
- SN04452131-W 20170331/170329235434-8c480fb36463c3e593f8c45735da2ebc (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |